Several CBD manufacturers would not speak on the record for fear of inviting federal retaliation, but said they’ve recently had trouble selling their products to non-cannabis retail stores. In January, the Seattle Central Co-op pulled CBD products from its shelves in reaction to the DEA rule. Meanwhile, CBD remains available online and at many retail health stores across the nation.
The majority of consumers who have used Serenity Hemp Oil 1000mg have experienced positive results. Several customers on amazon cite benefits in becoming more independent from opioid medications, in addition to better management of anxiety and sleeplessness. Many consumers on amazon say they enjoy the orange flavor and taste. Negative reviews are few for Serenity Hemp Oil 1000mg. The majority of those who have not had a positive experience claim an inability to assist with chronic pain and pain brought on by arthritis, something that could be achieved with CBD oils rather than hemp oil.
As mentioned above, CBD is no longer considered a Schedule I controlled substance under the Farm Act. However, under the DEA’s definition, it remains on the list. This allows for individual states to create exceptions to the status of CBD, even when cultivated from hemp plants grown legally under the act. It also maintains illegal status for any CBD sourced from plants produced in settings that are not consistent with that Act, or by an unlicensed grower. It is expected that more clarification on the status of CBD will come early this year (2019).
Another field in which CBD is creating a buzz is in the area of mood disorders like anxiety and depression. Both conditions have been treated with a variety of medications, courtesy of Big Pharma, that have had varying levels of success. Again, the long list of side effects can be off-putting to someone who just wants to get through the day without the sweaty tension of anxiety or the gray haze of depression.
Generalized pain, for instance, has dozens upon dozens of high profile research and clinical studies that have been carried out in universities and laboratories around the globe. One of the most well-publicized of these studies took place back in 2008, in which results determined that “cannabinoid analgesics (pain relievers) have generally been well tolerated in clinical trials … with acceptable adverse event profiles (meaning acceptable effectiveness for practical use).